Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms that no legally binding agreement has been ...
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo ...
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks Therapeutics. Das Portfolio des Unternehmens umfasst unter anderen das ...
"Given Merck KGaA’s existing franchise in oncology, which constitutes about 25% of its healthcare sales in 2024, we see the potential acquisition of SpringWorks as likely complementary and ...
On Wednesday, Morgan Stanley (NYSE:MS) downgraded Merck (NSE:PROR) KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00.
Germany’s Merck KGaA is in advanced talks to acquire SpringWorks, Reuters first reported Monday, citing people close to the matter. After the report, Merck KGaA later confirmed (PDF) the ...
09:50 EST Merck KGaA (MKGAY) in talks to buy SpringWorks Therapeutics (SWTX), Reuters reports Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing ...
NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...
Merck KGaA , the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics . Germany's Merck in ...
Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources. -- The deal could be finalized in the ...
Before that, she spent the better part of two decades at EMD Serono, Merck KGaA’s U.S. pharma subsidiary. Her 18 years there spanned a range of roles across its commercial team, including stints ...
NEW YORK/FRANKFURT (Reuters) - Merck (NSE:PROR) KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results